March 29, 2021 5:50pm

Volatility heightened during this holiday-shortened week with Q1-ending’ rebalancing among funds and risk avoidance from other investors

Pre-open indication results: 6 HITs and 1 MISS

News: UniQure NV (QURE +$0.93) shows its hemophilia B gene therapy likely wasn't the culprit in a patient's cancer diagnosis. Ionis Pharmaceuticals (IONS +$2.01) data from a P2 clinical study of IONIS-PKK-LRx met its primary and secondary endpoints, achieving significant reductions in the number of attacks suffered by patients with hereditary angioedema (HAE) compared to placebo. Cellectis S.A. (CLLS -$0.04) has filed a prospectus supplement with the SEC relating to an At-The-Market (ATM) program of up to $125 million of American Depositary Shares (ADS)

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence

Numbers based facts speak better then opinion as I see answers in numbers that equate to facts!

The Dow closed UP +98.49 points (+0.30%); the S&P closed DOWN -3.45 points (-0.09%) while the Nasdaq closed DOWN -79.08 points (-0.60%)



U.S. stocks (S&P and Nasdaq) fell and then gained on Monday amid weakness caught in the “supposed” downdraft of Friday’s margin calls as investors became more cautious as the month and quarter are about to end and institutional funds are rebalancing at the end of the quarter.

  • Although, stocks were taking a hit from the Archegos (fund) stumble, the situation is unlikely to have lasting impacts on the broader market.

Again, the stock market is closed for the Good Friday and Easter holiday as Passover also ends on 4/4/21.

The Dow (+7.2%) and the S&P 500 (+4.2%) have risen so far in March; while the Nasdaq dipped -1% this month.

And, traders are bracing for heightened volatility after Friday’s advances.


News (continued from title);

uniQure NV (QURE) the FDA placed QURE's hemophilia B test on a clinical hold in December after doctors diagnosed a patient with liver cancer. But new analyses show the gene therapy known as etranacogene dezaparvovec likely didn't cause the cancer.

Ionis Pharmaceuticals (IONS) the study demonstrated a mean reduction of 90% in the number of monthly HAE attacks in weeks one to 17 of the study (p <0.001) and a mean reduction of 97% in the number of monthly HAE attacks in weeks five to 17 (p=0.003). In weeks five to 17, 92% of patients treated with IONIS-PKK-LRx were attack-free compared to 0% in the placebo group (p <0.001).


RegMed Investors’ (RMi) pre-open: “RegMed Investors’ (RMi) pre-open: deal after reshuffling the deck with two (2) sessions left in month and quarter”      


Pre-open indication results:  6 HITs < Biostage (BSTG -$0.00 with 25 shares): Applied Genetic Technologies (AGTC -$0.33), Verastem (VSTM -$0.22), bluebird bio (BLUE +$0.96), Intellia Therapeutics (NTLA +$0.58), Editas Medicine (EDIT -$0.77), and 1 MISS < Pluristem (PSTI -$0.12)>


RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions

  • Monday opened negative at 8/24, 12 flat and 1 acquired, stayed negative at the mid-day to 6/26, 2 flat and 1 acquired, closing negative at 6/27, 1 flat and 1 acquired;


There are clear winners and losers

Jumping with share pricing momentum:

  • Ionis Pharmaceuticals (IONS), ReNeuron (RENE.L), bluebird bio (BLUE), uniQure NV (QURE), Intellia Therapeutics (NTLA) to name of the inclining of the 35 covered

Hammered in today’s market:

  • Alnylam Pharmaceuticals (ALNY), Ultragenyx (RARE), Sage Therapeutics (SAGE), CRISPR Therapeutics (CRSP), Chinook Therapeutics (KDNY) to name 5 of the 27 declining of the 35 covered


Key metrics:

  • Sector volume had LOW with 4 of the 6-upside having higher than the 3-month average volume with the volume of 0 of 27-downside having higher than the 3-month average volume;
  • Monday’s percentage (%) of the 6-upside were +0.85% (FATE) to +4.68% (IONS) while the 27-downside ranges from -0.21% (CLBS) to -9.15% (PGEN);


Monday’s (6 of 6) incline

  • Ionis Pharmaceuticals (IONS +$2.01 after Friday’s +$0.44);
  • ReNeuron (RENE.L +$2.00 after Friday’s -$5.00
  • bluebird bio (BLUE +$0.96 after Friday’s +$0.37
  • uniQure NV (QURE +$0.93 after Friday’s -$0.77);
  • Fate Therapeutics (FATE +$0.61 after Friday’s -$6.36),
  • Intellia Therapeutics (NTLA +$0.58 after Friday’s +$1.27

Monday’s (10 of 27) decliners:

  • Alnylam Pharmaceuticals (ALNY -$2.45 after Friday’s +$1.01
  • Sage Therapeutics (SAGE -$2.14 after Friday’s +$2.30);
  • Ultragenyx (RARE -$1.74 after Friday’s -$2.18
  • Chinook Therapeutics (KDNY -$1.08 after Friday’s -$0.57
  • Regenxbio (RGNX -$0.84);
  • Editas Medicine (EDIT -$0.77 after Friday’s -$1.70);
  • Precigen (PGEN -$0.68);
  • Vericel (VCEL -$0.59 after Friday’s -$2.67
  • MiMedx (MDXG -$0.58);
  • CRISPR Therapeutics (CRSP -$0.52 after Friday’s -$3.36

Closing: 1 – Biostage (BSTG) and 1 - Stemline Therapeutics (STML – acquired)


Sentiment and COVID-19 infections:

  • About 2.5 million people are receiving a vaccine every day, a figure that has been steady for more than a week. Most states expect to open eligibility to all adults by the end of April.

Infection cases <Million>: never to forget …

  • Monday 30.28 M cases,
  • Monday’s death rate totaled 548,867 <Johns Hopkins University>



The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB closed down -1.27% and XBI closed down -2.78%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was up +1.88 points or +9.97% at 20.74

Upside volume: low

  • Monday: 4 out of the 6-upside had higher than the 3-month average volume;

Downside volume: low

  • Monday: 0 out of the 27-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: % and pricing drop

  • Monday’s percentage (%) of the 6-upside were +0.85% (FATE) to +4.68% (IONS) while the 27-downside ranges from -0.21% (CLBS) to -9.15% (PGEN);


March, the 3rd month of Q1/21:

Monday (3/29) closed negative with 6 advancers, 27 decliners, 1 flat and 1 acquired


The BOTTOM LINE: Risky business and risk intolerance …

I have NEVER bought into near-term to focus on the short-term after algorithms and electronic trading manipulated short positions.

I follow ownership of stocks and their indications, riding each wave up and down, cashing-out before it goes down, then buying in again to ride it up again.

Who says, one can’t make it as a retail investor … trade it to make it!

“Again, my time horizon for HOLDING an equity is last Friday through Thursday (this week)” – think about that and check the Advance/Decline (A/D line) to VALIDATE my thesis.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.